Join us as we explore the transformative potential of Claudin 18.2 in the diagnosis and treatment of gastrointestinal cancers, such as gastric and gastro-oesophageal junction adenocarcinomas. This session will delve into the significance of CLDN18.2 as a biomarker, highlighting its role in identifying patients who may benefit from targeted therapies.